Business Context and Reporting Period
Mobia Medical, Inc. (formerly MicroTransponder, Inc.) is a commercial-stage medical device company focused on the Vivistim Paired Vagus Nerve Stimulation (Paired VNS) System, an FDA-approved solution for chronic ischemic stroke survivors with upper extremity impairments. This Form 10-Q covers the quarterly period ended March 31, 2026. The Company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $12.1 million | $5.7 million |
| Gross Profit | $9.9 million | $4.6 million |
| Gross Margin | 82.3% | 82.1% |
| Net Loss | $(17.7) million | $(10.7) million |
| Net Loss Per Share (Basic/Diluted) | $(19.30) | $(12.97) |
| Cash and Cash Equivalents (End of Period) | $55.7 million | $37.3 million |
| Accumulated Deficit | $(175.5) million | $(121.9) million |
| Operating Cash Flow | $(17.7) million | $(9.7) million |
| Financing Cash Flow | $39.9 million | $32.4 million |
Debt and Liquidity: As of March 31, 2026, the Company held $7.3 million in notes payable (net) and $40.0 million in convertible notes payable (fair value $40.7 million). The Company also had $26.4 million in convertible notes payable due to related parties. Total liabilities were $61.6 million.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 113.3% year-over-year, driven by a 108.9% increase in units of implanted pulse generators (IPGs) sold.
- Operating Expenses: Total operating expenses rose 79.8% to $26.9 million. Selling, general, and administrative (SG&A) expenses increased 85.2% to $25.2 million, primarily due to increased headcount in the commercial organization, higher commissions, and professional fees.
- Net Loss Expansion: Net loss increased 66.5% to $17.7 million, reflecting higher operating costs and a $0.7 million non-cash expense related to the change in fair value of convertible notes payable.
- Capital Structure: The Company issued $40.0 million in convertible promissory notes in January and February 2026. These notes were subsequently converted into common stock immediately prior to the IPO in May 2026.
Guidance, Outlook, and Risks
Subsequent Events (IPO): On May 11, 2026, the Company completed its Initial Public Offering (IPO), selling 10 million shares at $15.00 per share for net proceeds of approximately $134.5 million. Immediately prior to the IPO, all outstanding redeemable convertible preferred stock and the Q1 2026 convertible notes were converted into common stock.
Liquidity Outlook: Management believes that cash on hand combined with IPO proceeds will be sufficient to fund operations for at least the next 12 months. The Company expects to continue incurring losses as it scales its commercial organization and invests in R&D.
Material Weakness: The Company identified a material weakness in internal control over financial reporting related to the review of inputs in the calculation of net loss per share. This resulted in a revision to prior period EPS data. Remediation plans are underway.
Key Risks:
- Reimbursement: Commercial success depends on third-party payer coverage. While Medicare fee-for-service patients can access the therapy without prior authorization, commercial payers often require prior authorization, and some consider the therapy experimental.
- Supply Chain: The Company relies on single-source suppliers for critical components (IPG and leads). Disruptions could materially impact operations.
- Regulatory: Following a routine FDA inspection in March 2026, the Company received a Form 483 regarding medical device reporting timelines. The Company has submitted a corrective action plan.
Investor Verification Checklist
- Verify the status of the material weakness in internal controls and the timeline for remediation.
- Monitor reimbursement trends with commercial payers and the impact of the New Technology APC assignment effective January 1, 2026.
- Assess the conversion of debt and preferred stock into common stock post-IPO and the resulting dilution impact.
- Review the supply chain agreements with single-source manufacturers (Integer Holdings and Cirtec Medical) for potential disruption risks.
- Track the burn rate relative to the $134.5 million in IPO proceeds to validate the 12-month liquidity runway.